Hongjie Cai
Overview
Explore the profile of Hongjie Cai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
32
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cai H, Chen S, Tang S, Xiao Y, Shi F, Wu Z, et al.
Cancer Immunol Immunother
. 2025 Feb;
74(3):88.
PMID: 39891746
Background: Systemic and locoregional combination therapy has demonstrated promising outcomes for unresectable hepatocellular carcinoma (HCC); However, the best combination option remains unknown. This study compared the efficacy and safety of...
2.
Tang S, Shi F, Xiao Y, Cai H, Ma P, Zhou Y, et al.
Hepatol Int
. 2025 Jan;
19(1):106-117.
PMID: 39786672
Background/objective: The treatment strategy for hepatocellular carcinoma (HCC) with Vp4 (main trunk) portal vein tumor thrombosis (PVTT) remains controversial due to the dismal prognosis. We aimed to investigate the efficacy...
3.
Chen S, Zhao L, Wu Z, Cai H, Wang F, Wu L, et al.
Int Immunopharmacol
. 2024 Nov;
144:113662.
PMID: 39580864
Background: In advanced hepatocellular carcinoma (HCC), the triple combination therapy of hepatic arterial infusion chemotherapy (HAIC) with lenvatinib and programmed cell death protein-1 (PD-1) inhibitors has shown promise as a...
4.
Chen S, Shuangyan T, Shi F, Cai H, Wu Z, Wang L, et al.
Front Immunol
. 2024 Aug;
15:1430571.
PMID: 39131156
Background: Intermediate-stage (BCLC-B) hepatocellular carcinoma (HCC) beyond the up-to-11 criteria represent a significant therapeutic challenge due to high and heterogeneous tumor burden. This study evaluated the effectiveness and safety of...
5.
Zhao H, Cai H, Liu M
Med Image Anal
. 2024 Mar;
94:103140.
PMID: 38461655
The brain development during the perinatal period is characterized by rapid changes in both structure and function, which have significant impact on the cognitive and behavioral abilities later in life....
6.
Cai H, Chen S, Wu Z, Wang F, Tang S, Chen L, et al.
J Hepatocell Carcinoma
. 2024 Mar;
11:399-409.
PMID: 38435682
Purpose: Local in combination with systemic therapy might be an option for patients with advanced unresectable hepatocellular carcinoma (uHCC). This study examined the clinical benefits and adverse events (AEs) of...
7.
Liu D, Cai H, Zhou W, Lei D, Cao C, Xia X, et al.
RSC Adv
. 2024 Jan;
14(2):1501-1512.
PMID: 38178810
Photocatalysis is widely acknowledged as an efficient and environmentally friendly method for treating dye-contaminated wastewater. However, the utilization of powdered photocatalysts presents significant challenges, including issues related to recyclability and...
8.
Zhang R, Hong M, Cai H, Liang Y, Chen X, Liu Z, et al.
Quant Imaging Med Surg
. 2023 Dec;
13(12):7828-7841.
PMID: 38106261
Background: Radiomics models could help assess the benign and malignant invasiveness and prognosis of pulmonary nodules. However, the lack of interpretability limits application of these models. We thus aimed to...
9.
Chen S, Cai H, Wu Z, Tang S, Chen L, Wang F, et al.
Front Oncol
. 2023 Dec;
13:1235786.
PMID: 38074645
Purpose: To investigate the efficacy and safety of combined treatment of anlotinib and transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (uHCC) associated with hepatitis B virus (HBV) infection....
10.
Zhang Y, Zheng R, Liu M, Zhang X, Sun Y, Shen H, et al.
Ultrasound Med Biol
. 2023 Dec;
50(3):352-357.
PMID: 38072718
Objective: The aim of the work described here was to explore the value of contrast-enhanced ultrasound (CEUS) quantitative parameters in predicting the response of combined immune checkpoint inhibitor (ICI) and...